The partnership is aiming to collect and analyse digital biomarkers to identify signs of response and relapse in Beckley’s upcoming 5-MeO-DMT Phase 2 clinical trials.
Beckley Psytech and Ksana Health’s partnership will support the collection and analysis of digital behavioural data in the clinical trials.
Through the partnership, Beckley Psytech aims to track novel, predictive digital biomarkers to follow patient progress in the trials, which will be evaluating the use of 5-MeO-DMT in combination with psychotherapy in the treatment of treatment resistant depression (TRD).
CEO of Beckley Psytech, Cosmo Feilding Mellen, said: “This partnership with Ksana Health further supports our strategy to develop an integrated psychedelic treatment model, ensuring that patients are continuously supported throughout their treatment journey.
“We look forward to working with Ksana Health and exploring how their state-of-the-art digital technology can help support patient safety and response in our upcoming Phase 2 clinical trials.”
Using Ksana Health’s Effortless Assessment Research System (EARS), an end-to-end solution for mobile sensing, Beckley will collect passive mobile device metadata from clinical trial participants’ smartphones, in order to identify individual signals of potential response and relapse.
Co-founder and CEO of Ksana Health, Dr Nick Allen, commented: “Psychedelic treatments are offering exciting new approaches to recovery from mental disorders. However, we need rigorous clinical trials to ensure that this promise is realised.
“We are therefore very excited to partner with Beckley Psytech to help them build out their digital strategy. By using our continuous behavioural health measurement tools, we can help Beckley Psytech to understand each patient’s journey more deeply, which will ultimately allow for more effective and personalised treatments.”
The company has stated that this latest partnership further strengthens its digital strategy to develop personalised, end-to-end treatment programmes for patients in areas of significant unmet medical need.
[activecampaign form=52]
